EC Number | Application | Comment | Organism |
---|---|---|---|
3.4.21.91 | drug development | useful for the development of specific allosteric inhibitors designed to interfere with the productive interactions of NS2B with NS3pro | West Nile virus |
EC Number | Cloned (Comment) | Organism |
---|---|---|
3.4.21.91 | NS2B-NS3pro construct cloned into the pET101/D-TOPO vector C-terminally tagged with the His x 6 tag and expressed in Escherichia coli BL21(DE3) Codon Plus cells | West Nile virus |
EC Number | Protein Variants | Comment | Organism |
---|---|---|---|
3.4.21.91 | D42G | has no dramatic effect on either the catalytic activity (50% of wild-type) or self-proteolysis of NS2B-NS3pro. Aprotinin efficiently inhibits proteolytic activity | West Nile virus |
3.4.21.91 | G22S | resistant to autoproteolysis at the flexible linker region, retains 3% residual activity | West Nile virus |
3.4.21.91 | K48A | resistant to autoproteolysis at the flexible linker region. Aprotinin efficiently inhibits proteolytic activity | West Nile virus |
3.4.21.91 | additional information | D(32)DD(34) substitution for AAA inactivates NS2B-NS3pro, retains 1% residual activity | West Nile virus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.21.91 | Aprotinin | - |
West Nile virus |
EC Number | KM Value [mM] | KM Value Maximum [mM] | Substrate | Comment | Organism | Structure |
---|---|---|---|---|---|---|
3.4.21.91 | 0.004 | - |
pyroglutamic acid-Arg-Thr-Lys-Arg-7-amido-4-methylcoumarin | mutant G22S | West Nile virus | |
3.4.21.91 | 0.004 | - |
butyloxycarbonyl-Arg-Val-Arg-Arg-7-amido-4-methylcoumarin | mutant G22S | West Nile virus | |
3.4.21.91 | 0.03 | - |
pyroglutamic acid-Arg-Thr-Lys-Arg-7-amido-4-methylcoumarin | wild-type | West Nile virus | |
3.4.21.91 | 0.03 | - |
butyloxycarbonyl-Arg-Val-Arg-Arg-7-amido-4-methylcoumarin | wild-type | West Nile virus |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.21.91 | West Nile virus | P06935 | - |
- |
3.4.21.91 | West Nile virus NY99 | P06935 | - |
- |
EC Number | Purification (Comment) | Organism |
---|---|---|
3.4.21.91 | NS2B-NS3pro construct purified by Co2+-chelating Sepharose Fast Flow chromatography | West Nile virus |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.21.91 | butyloxycarbonyl-Arg-Val-Arg-Arg-7-amido-4-methylcoumarin + H2O | - |
West Nile virus | butyloxycarbonyl-Arg-Val-Arg-Arg + 7-amino-4-methylcoumarin | - |
? | |
3.4.21.91 | butyloxycarbonyl-Arg-Val-Arg-Arg-7-amido-4-methylcoumarin + H2O | - |
West Nile virus NY99 | butyloxycarbonyl-Arg-Val-Arg-Arg + 7-amino-4-methylcoumarin | - |
? | |
3.4.21.91 | myelin basic protein + H2O | - |
West Nile virus | ? | - |
? | |
3.4.21.91 | myelin basic protein + H2O | - |
West Nile virus NY99 | ? | - |
? | |
3.4.21.91 | pyroglutamic acid-Arg-Thr-Lys-Arg-7-amido-4-methylcoumarin + H2O | - |
West Nile virus | pyroglutamic acid-Arg-Thr-Lys-Arg + 7-amino-4-methylcoumarin | - |
? | |
3.4.21.91 | pyroglutamic acid-Arg-Thr-Lys-Arg-7-amido-4-methylcoumarin + H2O | - |
West Nile virus NY99 | pyroglutamic acid-Arg-Thr-Lys-Arg + 7-amino-4-methylcoumarin | - |
? |
EC Number | Synonyms | Comment | Organism |
---|---|---|---|
3.4.21.91 | NS2B-NS3 proteinase | - |
West Nile virus |
EC Number | Cofactor | Comment | Organism | Structure |
---|---|---|---|---|
3.4.21.91 | NS2B protein | the G(22) residue and the negatively charged patch D(32)DD(34) of NS2B are part of an important configuration required for NS2B-NS3pro activity | West Nile virus |